144 In the index

ARA-290 ARA-290

A peptide related to the hormone erythropoietin but without its blood-thickening effects, tested in humans for nerve pain. Trials show it reduces pain and improves nerve health in specific patient groups, without the blood-related risks that come with full erythropoietin.

Also known as Cibinetide, PHBSP, PH-BSP, ARA 290, pHBSP peptide, Cibinetida, 9W5677JKDA, pyroglutamate helix B surface peptide

Effects Heal

Routes Subcutaneous

Legal status Research chemical

WADA Not listed

Molecular Structure of C₅₁H₈₄N₁₆O₂₁

Drag to rotate · scroll to zoom

PubChem has no 3D conformer for this molecule, so this is the flat structure.

Chemistry

Formula: C51H84N16O21
Molar mass: 1257.3
CAS: 1208243-50-8
PubChem CID: 91810664
IUPAC name: (4S)-5-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-oxo-4-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoic acid
InChIKey: WZTIQQBMSJTRBR-WYKNNRPVSA-N

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not established for general use

Reported range Clinical trials: roughly 1-4 mg subcutaneous

Route Subcutaneous injection

Frequency Varies by trial (daily to a few times weekly)

Duration Trial durations of several weeks

Studied in small clinical trials (as Cibinetide) for sarcoidosis-associated neuropathic pain; not an approved product.

Where this comes from Published Phase II clinical trial data

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.